Skip to main content

Erdafitinib Approved for Locally Advanced or Metastatic Urothelial Cancer

The FDA has granted approval to erdafitinib (Balversa™, Janssen Biotech) for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy. Patients are not recommended to receive treatment with erdafitinib if they are eligible for and have not received pri...

Continue reading